Biologics Safety Testing Market (By offering - Instruments, Kits and Reagents, and Services; By Test Type - Bioburden tests, Endotoxin tests, Sterility tests, Adventitious Agent Detection tests, Cell Line Authentication and Characterization tests, Residual Host Contaminant Detection tests, and Other tests; By Application - Vaccine and Therapeutics Development, Cell and Gene Therapy, Blood and Blood-related Products testing, Tissue and Tissue-related products testing, and Stem Cell Research.; By End user - Pharmaceutical and Biotechnology companies, Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), Academic and Research Institutes, and Government and Regulatory Testing Laboratories; By Distribution channel - Direct institutional sales, Distributor Networks, and Online/digital Procurement Platforms): Global Industry Analysis, Trends, Size, Share and Forecasts to 2035

A recent report published by Infinium Global Research on biologics safety testing market provides in-depth analysis of segments and sub-segments in the global as well as regional biologics safety testing market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional biologics safety testing market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global biologics safety testing market.

Market Insight:

11.60 %

This Infinium Global Research report presents an updated assessment of the Global Biologics Safety Testing Market for the 2026–2035 outlook period. Biologics safety testing, for the purposes of this study, encompasses the instruments, kits and reagents, and contract testing services used to verify the safety, purity, and quality of biologic products, including vaccines, monoclonal antibodies, recombinant proteins, blood and blood-related products, tissue and tissue-related products, stem cell therapies, and cell and gene therapies, prior to clinical use or commercial release. The scope spans bioburden testing, endotoxin testing, sterility testing, adventitious agent detection testing, cell line authentication and characterization testing, and residual host contaminant detection testing. This edition recalibrates market sizing, segmentation, competitive positioning, and regional dynamics to reflect a decade of structural change, including the rapid expansion of cell and gene therapy pipelines, the rise of recombinant Factor C (rFC) as an animal-free alternative to traditional LAL-based endotoxin testing, and continued consolidation among leading contract testing organizations.

Among application categories, cell and gene therapy presents the most attractive investment case, reflecting the substantially more complex and specialized safety testing requirements, including replication-competent lentivirus testing and comprehensive viral clearance studies, that these advanced therapies demand relative to conventional biologics. Within end-user segments, CDMOs and CROs are gaining relative attractiveness as sponsors increasingly outsource testing to specialized providers with rapid-method validation capability, even as pharmaceutical and biotechnology companies retain the largest overall share of testing-linked spending. Instruments and automated platforms, though a smaller share of total offering-segment value relative to services, are increasingly attractive to manufacturers as rapid sterility and endotoxin testing technologies gain adoption among CDMOs and biotech developers seeking to compress product release cycle times.

1 North America North America remains the largest regional biologics safety testing market. Growth continues to be underpinned by the region's high concentration of biopharmaceutical R&D activity, a mature and well-established U.S. FDA regulatory framework, and the presence of leading contract testing organizations' headquarters and largest laboratory networks. The United States represents the region's dominant market, supported by substantial venture funding flows into cell and gene therapy and immuno-oncology development programs, each of which generates outsized safety testing demand. Canada contributes a smaller but steadily developing market shaped by similar biopharmaceutical R&D activity trends. 2 Europe Europe remains the second-largest regional market, benefiting from a centralized European Medicines Agency regulatory pathway that concentrates market activity in Germany, Switzerland, and Ireland. France and Italy are scaling CAR-T cell therapy testing capacity through public-private partnerships, boosting regional testing capacity for advanced therapy medicinal products. The United Kingdom's divergent post-Brexit viral-safety testing rules require dual testing strategies for sponsors pursuing pan-European product launches, a regulatory complexity that has modestly increased testing costs for sponsors operating across both UK and EU markets over the past few years which predated the UK's departure from the European Union. 3 Asia Pacific Asia Pacific stands out, as the fastest-growing market, as the region posting the highest percentage growth over the current forecast period as well, with recent estimates placing regional growth at approximately 12.5% CAGR through 2035. China's National Medical Products Administration has continued aligning its regulatory framework with International Council for Harmonisation standards, facilitating rapid-method testing adoption, while Japan has reduced sterility testing hold times to seven days, further accelerating regional testing throughput. Rising CDMO investment, exemplified by Samsung Biologics' expanding quality control suite capacity in Incheon, South Korea, and WuXi AppTec's EMA release-site-accredited Shanghai laboratory, underscores the region's growing role as both a biomanufacturing and biologics safety testing hub. 4 Latin America Latin America represents an emerging growth market, with Brazil serving as the primary demand center given its expanding biopharmaceutical manufacturing base and growing government investment in domestic biologics production capability, reducing historical reliance on imported biologic products and associated testing services. 5 Middle East & Africa The Middle East & Africa region represents the smallest but an emerging biologics safety testing market, with Gulf Cooperation Council countries driving gradual regional demand growth through healthcare infrastructure investment and nascent domestic biopharmaceutical manufacturing initiatives. Sub-Saharan African markets remain at an earlier stage of biologics safety testing market development, constrained by more limited biomanufacturing infrastructure, though international donor-funded vaccine manufacturing initiatives are expected to support gradual long-term growth.

Report Scope of the Biologics Safety Testing Market:

Segment wise revenue contribution in the global biologics safety testing market

The report on global biologics safety testing market provides a detailed analysis of segments in the market based on By offering , By Test Type, By Application, By End user, and By Distribution channel.

Segmentation Based on By offering

·       Instruments

·       Kits and Reagents

·       Services

Segmentation Based on By Test Type

·       Bioburden tests

·       Endotoxin tests

·       Sterility tests

·       Adventitious Agent Detection tests

·       Cell Line Authentication and Characterization tests

·       Residual Host Contaminant Detection tests

·       Other tests

Segmentation Based on By Application

·       Vaccine and Therapeutics Development

·       Cell and Gene Therapy

·       Blood and Blood-related Products testing

·       Tissue and Tissue-related products testing

·       Stem Cell Research.

Segmentation Based on By End user

·       Pharmaceutical and Biotechnology companies

·       Contract Development and Manufacturing Organizations (CDMOs)

·       Contract Research Organizations (CROs)

·       Academic and Research Institutes

·       Government and Regulatory Testing Laboratories

Segmentation Based on By Distribution channel

·       Direct institutional sales

·       Distributor Networks

·       Online/digital Procurement Platforms

Company Profiled:

·       Charles River Laboratories International, Inc.

·       Thermo Fisher Scientific Inc.

·       Lonza Group Ltd.

·       Merck KGaA (MilliporeSigma)

·       Eurofins Scientific SE

·       SGS SA

·       Sartorius AG

·       WuXi AppTec Co., Ltd.

·       Toxikon Corporation (a Labcorp company)

·       Cytovance Biologics, Inc

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the biologics safety testing market. Moreover, the study highlights current market trends and provides forecasts from 2026-2035. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.